Significant Inflows Observed in ETFs - SPYD, CVS, VTRS, HPQ
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 05 2025
0mins
Source: NASDAQ.COM
SPYD Share Price Analysis: SPYD's current share price is $44.97, with a 52-week low of $37.92 and a high of $47.52, indicating its performance within the trading range.
Understanding ETFs: Exchange traded funds (ETFs) function like stocks, with investors buying and selling "units" that can be created or destroyed based on demand, affecting the underlying holdings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 90.730
Low
91.00
Averages
96.71
High
105.00
Current: 90.730
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Close Higher: S&P 500 Hits All-Time High
- Market Performance: The S&P 500 rose by 0.61% and the Nasdaq 100 increased by 1.76%, reaching all-time highs, indicating strong demand for tech stocks amid falling oil prices and progress in US-Iran peace talks.
- Oil Price Volatility: WTI crude oil prices fell to a 2.5-week low as US-Iran negotiations aimed at reopening the Strait of Hormuz progressed, although military actions by US Central Command pressured market sentiment, leading to declines in energy stocks.
- Economic Data Impact: The Chicago Fed National Activity Index rose to a 13-month high of 0.14, surpassing expectations, while a slight decline in the consumer confidence index reflects the complexities of economic recovery, potentially influencing future market trends.
- Earnings Reports: As of Tuesday, 83% of the 475 S&P 500 companies reported earnings above expectations, with Q1 earnings projected to grow by 12% year-on-year, although excluding the tech sector, the increase is only 3%, highlighting disparities across industries.
See More
US Stock Indices Rally, Led by Technology Stocks
- Strong Market Performance: The S&P 500 Index rose by 0.81% and the Nasdaq 100 Index increased by 1.74%, reaching all-time highs, indicating robust market support for technology stocks, particularly amid falling crude oil prices and declining bond yields.
- Mixed Economic Data: The Chicago Fed National Activity Index rose to a 13-month high of 0.14, surpassing expectations, while the S&P Composite-20 home price index increased by only 0.83% year-on-year, below the expected 0.90%, suggesting weakness in the housing market that could impact future consumer confidence.
- Volatile Oil Market: WTI crude oil prices fell to a 2.5-week low due to progress in US-Iran peace talks, although US Central Command's strikes on Iranian targets caused market fluctuations, highlighting the ongoing geopolitical influence on energy markets.
- Earnings Season Insights: So far, 83% of the 475 S&P 500 companies have beaten earnings estimates, with Q1 earnings projected to rise by 12% year-on-year; however, excluding the technology sector, the increase is only 3%, reflecting pressure on overall economic growth.
See More
CVS Sues Tennessee to Block Pharmacy Closure Legislation
- Legal Challenge: On May 22, CVS filed a lawsuit in Nashville to block Tennessee's new law that would force the closure of its 136 pharmacies in the state, impacting over 2,000 employees and 1.5 million patients' access to medications.
- Legislative Background: The law, signed by Governor Bill Lee, prohibits companies from owning both pharmacies and pharmacy benefit managers (PBMs), taking effect on July 1, 2028; CVS claims this law undermines patient interests and restricts fair competition.
- Industry Impact: CVS spokesperson stated that the law would increase prescription drug costs and would not lower costs for anyone, highlighting the growing regulatory scrutiny on large healthcare corporations amid congressional and state-level focus on drug pricing.
- Lawsuit Objectives: CVS's lawsuit seeks a federal judge's ruling that the law violates federal statutes and aims to prevent Tennessee from implementing it, naming the Tennessee Board of Pharmacy and other officials as defendants, demonstrating CVS's strong opposition and commitment to protecting patient rights.
See More
Glenview Capital's Investment Review of CVS Health
- Significant Investment Returns: Since May 2024, CVS Health shares have generated an 80% total return, reflecting the company's positive progress in cultural and operational turnaround, indicating an increase in long-term investment value.
- Strategic Holdings Adjustment: Glenview rebalanced its holdings in May 2025 and 2026, reducing CVS shares by 3.75 million to align with the fund's diversification parameters while creating capital for further investment opportunities in a volatile macro environment.
- Ongoing Confidence: Despite the adjustments, CVS Health remains one of Glenview's top three holdings, with management expressing strong confidence in CVS's near, medium, and long-term outlook, highlighting its stability and potential in the market.
- Enhanced Operational Efficiency: CVS Health has improved drug reimbursement processes and expedited medical claims handling through increased operational intensity and transparency, positively impacting the health and well-being of the majority of Americans, showcasing its innovative leadership in the industry.
See More
CVS Health Invests in Senior Housing in New Jersey
- Housing Investment Scale: CVS Health's $9 million investment through R4 Capital, in collaboration with Diocesan Housing Services Corporation and The Walters Group, supports the development of a 75-unit affordable housing project for seniors in Williamstown, New Jersey, reflecting the company's long-standing commitment to improving community health.
- Diverse Funding Sources: The project secured $8 million in HUD funding, $14 million in NJHMFA construction financing, and $7 million from the Affordable Housing Production Fund, highlighting the importance of multi-party collaboration in addressing the housing needs of older adults.
- Addressing Housing Burden: With 60% of New Jersey renters aged 65 and older facing housing cost burdens, CVS Health's investment not only meets the urgent need for affordable housing but also helps residents live safely and independently by providing personalized medical and social services.
- Significant Economic Impact: CVS Health's operations in New Jersey are projected to generate an estimated $12.5 billion economic impact in 2024, supporting over 39,000 jobs while contributing approximately $882.1 billion in state and local taxes, further solidifying its vital role in the community.
See More
CVS Health Stock Rises 24%: Key Growth Drivers
- Earnings Surprise: CVS reported a 6.2% year-over-year revenue increase to $100.4 billion in Q1, exceeding analyst expectations of $94.4 billion, with EPS at $2.30, a 62% rise, prompting the company to raise its full-year guidance, now forecasting EPS between $6.24 and $6.44 and operational cash flow of at least $9.5 billion, indicating robust financial health.
- Attractive Dividend Yield: With a current dividend yield of approximately 2.8%, more than double the S&P 500 average, CVS's consistent free cash flow, ranging from $9 billion to $10.5 billion in recent years, supports its dividend payments, enhancing investor confidence.
- Insurance Segment Recovery: CVS's health insurance unit Aetna saw a 3.3% revenue increase to $35.9 billion, with improved margins due to reduced medical utilization costs, as the medical benefit ratio dropped from 87.3% to 84.6%, reflecting strategic adjustments to enhance insurance profitability.
- Debt Concerns Persist: While CVS shows signs of improving profitability, its long-term debt of $86.4 billion remains a drag on performance, with a capital-intensive acquisition strategy leading to significant interest expenses, although total debt has decreased by 1.5% year-over-year to $175 billion, warranting attention on its impact on expansion and stock buybacks.
See More
US Stocks Close Higher: S&P 500 Hits All-Time High
- Market Performance: The S&P 500 rose by 0.61% and the Nasdaq 100 increased by 1.76%, reaching all-time highs, indicating strong demand for tech stocks amid falling oil prices and progress in US-Iran peace talks.
- Oil Price Volatility: WTI crude oil prices fell to a 2.5-week low as US-Iran negotiations aimed at reopening the Strait of Hormuz progressed, although military actions by US Central Command pressured market sentiment, leading to declines in energy stocks.
- Economic Data Impact: The Chicago Fed National Activity Index rose to a 13-month high of 0.14, surpassing expectations, while a slight decline in the consumer confidence index reflects the complexities of economic recovery, potentially influencing future market trends.
- Earnings Reports: As of Tuesday, 83% of the 475 S&P 500 companies reported earnings above expectations, with Q1 earnings projected to grow by 12% year-on-year, although excluding the tech sector, the increase is only 3%, highlighting disparities across industries.
See More
US Stock Indices Rally, Led by Technology Stocks
- Strong Market Performance: The S&P 500 Index rose by 0.81% and the Nasdaq 100 Index increased by 1.74%, reaching all-time highs, indicating robust market support for technology stocks, particularly amid falling crude oil prices and declining bond yields.
- Mixed Economic Data: The Chicago Fed National Activity Index rose to a 13-month high of 0.14, surpassing expectations, while the S&P Composite-20 home price index increased by only 0.83% year-on-year, below the expected 0.90%, suggesting weakness in the housing market that could impact future consumer confidence.
- Volatile Oil Market: WTI crude oil prices fell to a 2.5-week low due to progress in US-Iran peace talks, although US Central Command's strikes on Iranian targets caused market fluctuations, highlighting the ongoing geopolitical influence on energy markets.
- Earnings Season Insights: So far, 83% of the 475 S&P 500 companies have beaten earnings estimates, with Q1 earnings projected to rise by 12% year-on-year; however, excluding the technology sector, the increase is only 3%, reflecting pressure on overall economic growth.
See More
CVS Sues Tennessee to Block Pharmacy Closure Legislation
- Legal Challenge: On May 22, CVS filed a lawsuit in Nashville to block Tennessee's new law that would force the closure of its 136 pharmacies in the state, impacting over 2,000 employees and 1.5 million patients' access to medications.
- Legislative Background: The law, signed by Governor Bill Lee, prohibits companies from owning both pharmacies and pharmacy benefit managers (PBMs), taking effect on July 1, 2028; CVS claims this law undermines patient interests and restricts fair competition.
- Industry Impact: CVS spokesperson stated that the law would increase prescription drug costs and would not lower costs for anyone, highlighting the growing regulatory scrutiny on large healthcare corporations amid congressional and state-level focus on drug pricing.
- Lawsuit Objectives: CVS's lawsuit seeks a federal judge's ruling that the law violates federal statutes and aims to prevent Tennessee from implementing it, naming the Tennessee Board of Pharmacy and other officials as defendants, demonstrating CVS's strong opposition and commitment to protecting patient rights.
See More
Glenview Capital's Investment Review of CVS Health
- Significant Investment Returns: Since May 2024, CVS Health shares have generated an 80% total return, reflecting the company's positive progress in cultural and operational turnaround, indicating an increase in long-term investment value.
- Strategic Holdings Adjustment: Glenview rebalanced its holdings in May 2025 and 2026, reducing CVS shares by 3.75 million to align with the fund's diversification parameters while creating capital for further investment opportunities in a volatile macro environment.
- Ongoing Confidence: Despite the adjustments, CVS Health remains one of Glenview's top three holdings, with management expressing strong confidence in CVS's near, medium, and long-term outlook, highlighting its stability and potential in the market.
- Enhanced Operational Efficiency: CVS Health has improved drug reimbursement processes and expedited medical claims handling through increased operational intensity and transparency, positively impacting the health and well-being of the majority of Americans, showcasing its innovative leadership in the industry.
See More
CVS Health Invests in Senior Housing in New Jersey
- Housing Investment Scale: CVS Health's $9 million investment through R4 Capital, in collaboration with Diocesan Housing Services Corporation and The Walters Group, supports the development of a 75-unit affordable housing project for seniors in Williamstown, New Jersey, reflecting the company's long-standing commitment to improving community health.
- Diverse Funding Sources: The project secured $8 million in HUD funding, $14 million in NJHMFA construction financing, and $7 million from the Affordable Housing Production Fund, highlighting the importance of multi-party collaboration in addressing the housing needs of older adults.
- Addressing Housing Burden: With 60% of New Jersey renters aged 65 and older facing housing cost burdens, CVS Health's investment not only meets the urgent need for affordable housing but also helps residents live safely and independently by providing personalized medical and social services.
- Significant Economic Impact: CVS Health's operations in New Jersey are projected to generate an estimated $12.5 billion economic impact in 2024, supporting over 39,000 jobs while contributing approximately $882.1 billion in state and local taxes, further solidifying its vital role in the community.
See More
CVS Health Stock Rises 24%: Key Growth Drivers
- Earnings Surprise: CVS reported a 6.2% year-over-year revenue increase to $100.4 billion in Q1, exceeding analyst expectations of $94.4 billion, with EPS at $2.30, a 62% rise, prompting the company to raise its full-year guidance, now forecasting EPS between $6.24 and $6.44 and operational cash flow of at least $9.5 billion, indicating robust financial health.
- Attractive Dividend Yield: With a current dividend yield of approximately 2.8%, more than double the S&P 500 average, CVS's consistent free cash flow, ranging from $9 billion to $10.5 billion in recent years, supports its dividend payments, enhancing investor confidence.
- Insurance Segment Recovery: CVS's health insurance unit Aetna saw a 3.3% revenue increase to $35.9 billion, with improved margins due to reduced medical utilization costs, as the medical benefit ratio dropped from 87.3% to 84.6%, reflecting strategic adjustments to enhance insurance profitability.
- Debt Concerns Persist: While CVS shows signs of improving profitability, its long-term debt of $86.4 billion remains a drag on performance, with a capital-intensive acquisition strategy leading to significant interest expenses, although total debt has decreased by 1.5% year-over-year to $175 billion, warranting attention on its impact on expansion and stock buybacks.
See More
